Medical and Surgical Dermatology Journal

Overview
Identity
View All

publication venue for

Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study. 2024
Management of Guttate Psoriasis: A Systematic Review. 12034754241266187. 2024
Applications of Machine Learning on Alopecia Areata: A Systematic Review. 28:303-304. 2024
Machine Learning Applications in Psoriasis Treatment: A Systematic Review. 28:301-302. 2024
Association Between Parkinson’s Disease and Psoriasis: A Scoping Review. 28:72-73. 2024
Evaluation of Vision LLMs GTP-4V and LLaVA for the Recognition of Features Characteristic of Melanoma. 28:98-99. 2024
GLP-1R Agonists in Psoriasis Patients. 28:91-92. 2024
Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review. 28:86-87. 2024
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). 27:594-600. 2023
A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. 27:358-367. 2023
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. 27:3S-24S. 2023
Under-Reporting of COVID-19 Infections in Psoriasis Patients on Biologics. 27:75-76. 2023
Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. 26:3S-23S. 2022
Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers. 26:267-273. 2022
Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. 26:319-320. 2022
A Useful Clinical Tool for Psoriasis. 25:648-649. 2021
A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic. 25:298-302. 2021
Retrospective Study of Patients With SJS/TEN Treated at a Tertiary Burn Unit in Canada: Overview of 17 Years of Treatment. 25:271-280. 2021
Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 Can Be Divided Into Inflammatory and Vascular Patterns. 25:169-176. 2021
A Review of Drug-Drug Interactions for Biologic Drugs Used in the Treatment of Psoriasis. 25:38-44. 2021
The Incidence and Prevalence of Uveitis in Psoriasis: A Systematic Review and Meta-Analysis. 24:601-607. 2020
Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. 24:3S-14S. 2020
Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice. 24:418-419. 2020
Canadian Burden of Skin Disease From 1990 to 2017: Results From the Global Burden of Disease 2017 Study. 24:161-173. 2020
Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?. 23:586-594. 2019
The Role of IL-17 in Papulopustular Rosacea and Future Directions. 23:635-641. 2019
Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. 23:391-393. 2019
Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. 23:282-288. 2019
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. 23:50-74. 2019
Canadian Patients’ Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys. 22:464-471. 2018
Sunnybrook Protocol for Treatment of Toxic Epidermal Necrolysis. 22:535-535. 2018
Toxic Epidermal Necrolysis Spectrum Management at Sunnybrook Health Sciences Centre: Our Multidisciplinary Approach After Review of the Current Evidence. 22:213-219. 2018
A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. 22:78-83. 2018
Undergraduate Dermatology Education in Canada: A National Survey. 22:31-37. 2018
Acitretin Use in Dermatology. 21:2S-12S. 2017
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. 21:2S-40S. 2017
An Open Letter to Health Canada. 21:195-196. 2017
Review of Systemic Treatment Options for Adult Atopic Dermatitis. 21:31-39. 2017
2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. 20:375-431. 2016
Acral Hemorrhagic Darier’s Disease. 20:478-480. 2016
Psoronychomycosis. 20:279-280. 2016
Borderline Lepromatous Leprosy. 20:176-177. 2016
The Relationship Between Dermatologist- and Patient-Reported Acne Severity Measures and Treatment Recommendations. 19:464-469. 2015
Non-melanoma Skin Cancer in Canada Chapter 1: Introduction to the Guidelines. 19:205-215. 2015
Non-melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer. 19:216-226. 2015
Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses. 19:227-238. 2015
Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma. 19:239-248. 2015
Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma. 19:249-259. 2015
Paradoxical, Cupping-Induced Localized Psoriasis: A Koebner Phenomenon. 19:320-322. 2015
Public Engagement with Dermatology Contents on Facebook. 19:304-308. 2015
Recall Dermatitis to Metronidazole. 19:326-327. 2015
Think beyond the Skin. 19:22-27. 2015
Use of Facebook as a Tool for Knowledge Dissemination in Dermatology. 18:341-344. 2014
A Consensus on Acne Management Focused on Specific Patient Features. 18:243-255. 2014
Unilateral Hand Allergic Contact Dermatitis due to Occupational Exposure. 18:283-286. 2014
Surface Anatomy of the Ear. 18:137-140. 2014
Clinical features of external genital warts.. 17 Suppl 2:S55-S60. 2013
Managing external genital warts: practical aspects of treatment and prevention.. 17 Suppl 2:S68-S75. 2013
Therapeutic options for external genital warts.. 17 Suppl 2:S61-S67. 2013
Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus.. 17 Suppl 2:S47-S54. 2013
One-Year, Multicenter, Open-Label, Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population. 17:129-138. 2013
Sulfa or Sulfur? Clearing Things up. 17:79-81. 2013
Surface Anatomy of the Nose for the Dermatologist. 17:143-146. 2013
Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice. 16:407-416. 2012
Comparison of Dermatologists' and Nondermatologists' Diagnostic Accuracy for Malignant Melanoma. 16:272-280. 2012
Unilateral Keratoderma in a Mother and Her Son. 16:288-290. 2012
Impact of the Number of Dermatologists on Dermatology Biomedical Research: A Canadian Study. 16:174-179. 2012
Sweet Syndrome and Pemphigus Vulgaris. 16:128-130. 2012
Figurate Erythema: An Unusual Presentation of the Nonbullous Phase of Bullous Pemphigoid. 16:61-63. 2012
Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations. 15:309-321. 2011
Canadian Guidelines for the Management of Plaque Psoriasis: Overview. 15:210-219. 2011
Gourmet Clinical Pearls. 15:63-64. 2011
Drug-Induced Lichenoid Dermatitis with Histopathologic Features of Mycosis Fungoides in a Patient with Psoriasis. 14:307-309. 2010
Antepartum Intravenous Immunoglobulin Therapy in Refractory Pemphigoid Gestationis: Case Report and Literature Review. 14:189-192. 2010
Development and Validation of a Scale for Acne Scar Severity (SCAR-S) of the Face and Trunk. 14:156-160. 2010
Are Excipients Really Inert Ingredients? A Review of Adverse Reactions to Excipients in Oral Dermatologic Medications in Canada. 14:105-114. 2010
Efficacy Outcomes in Patients Using Alefacept in the AWARE Study. 13:S122-S130. 2009
Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies. 13:S58-S66. 2009
Effect of Quality of Life Impact and Clinical Severity on Adherence to Topical Acne Treatment. 13:204-208. 2009
Skin Thickening in a Hemodialysis Patient: A Case of Nephrogenic Fibrosing Dermopathy. 13:110-114. 2009
Nail Psoriasis and Biologics. 13:1-5. 2009
Occurrence of Plantar Pustular Psoriasis during Treatment with Infliximab. 13:40-42. 2009
Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics. 12:282-287. 2008
Psychopharmacology in Psychodermatology. 12:255-267. 2008
Are All Seborrheic Keratoses Benign? Review of the Typical Lesion and Its Variants. 12:203-210. 2008
Divergence of Demographic Factors Associated with Clinical Severity Compared with Quality of Life Impact in Acne. 12:235-242. 2008
Development and Validation of a Comprehensive Acne Severity Scale. 11:211-216. 2007
Miliarial Gout (A New Entity). 11:31-34. 2007
Multitherapy Approach to Onychomycosis Therapy. 10:S44-S47. 2006
Prevalence and Epidemiology of Onychomycosis. 10:S28-S33. 2006
Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature. 10:128-130. 2006
Antihistamines in the Treatment of Atopic Dermatitis. 7:467-473. 2003
When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant?. 7:387-389. 2003
When is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant?. 7:387-389. 2003
Mycophenolate Mofetil (CellCept�) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. 7:193-197. 2003
Treatment of self-mutilation with olanzapine.. 4:161-163. 2000
Monetary and Nonmonetary Costs to Patients Attending an Ambulatory Dermatology Clinic. 3:188-192. 1999
Role of the Cyclin-Dependent Kinase Inhibitor CDKN2A in Familial Melanoma. 2:172-179. 1998
Current Thoughts on the Use of Methotrexate in Patients with Psoriasis. 2:41-46. 1997